Key Insights

Highlights

Success Rate

86% trial completion

Published Results

80 trials with published results (8%)

Research Maturity

359 completed trials (38% of total)

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 62/100

Termination Rate

6.2%

59 terminated out of 955 trials

Success Rate

85.9%

-0.6% vs benchmark

Late-Stage Pipeline

8%

79 trials in Phase 3/4

Results Transparency

22%

80 of 359 completed with results

Key Signals

80 with results86% success59 terminated

Data Visualizations

Phase Distribution

693Total
Not Applicable (301)
Early P 1 (2)
P 1 (86)
P 2 (225)
P 3 (73)
P 4 (6)

Trial Status

Completed359
Unknown221
Recruiting172
Not Yet Recruiting71
Terminated59
Active Not Recruiting44

Trial Success Rate

85.9%

Benchmark: 86.5%

Based on 359 completed trials

Clinical Trials (955)

Showing 20 of 20 trials
NCT06274190Not ApplicableRecruitingPrimary

Personalized Care Pathways for Bowel Symptoms in Rectal Cancer patients_development of E-diary

NCT03144765Not ApplicableActive Not RecruitingPrimary

Multicenter Phase II Study of Transanal TME (taTME)

NCT07528209Phase 3RecruitingPrimary

Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer

NCT07527520Phase 2Not Yet RecruitingPrimary

Neoadjuvant Moderately Hypofractionated Radiotherapy Combined With Chemotherapy and Immunotherapy for High-risk pMMR/MSS Locally Advanced Rectal Cancer: A Prospective, Multi-center Randomized Control Phase II Trial

NCT06205485Phase 3RecruitingPrimary

Neoadjuvant Chemotherapy, Excision And Observation vs Chemoradiotherapy For Rectal Cancer

NCT07501845RecruitingPrimary

Registry Maastro Applicator

NCT07404228Not Yet RecruitingPrimary

Multidimensional Study Designed to Develop a Methodological Framework Based on MRI Data to Predict Pathological Complete Response (pCR) in Patients With Locally Advanced Rectal Cancer After Neoadjuvant Treatment

NCT03259035Phase 2CompletedPrimary

NEO: Neoadjuvant Chemotherapy, Excision and Observation for Early Rectal Cancer

NCT06162650Phase 2RecruitingPrimary

Total Neoadjuvant Therapy in Rectal Cancer

NCT05515796Phase 2Completed

Multi-omics Sequencing in Neoadjuvant Immunotherapy of Gastrointestinal Tumors

NCT07505472Phase 2RecruitingPrimary

Efficacy and Safety Comparison of Short-course Radiotherapy Followed by CapeOX Chemotherapy Plus Toripalimab With or Without Concurrent Surufatinib in Neoadjuvant Therapy for Mid-to-low Localized Rectal Cancer of High-risk Criteria

NCT04963283Phase 2Active Not Recruiting

Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer

NCT02437656Phase 2CompletedPrimary

Combination of Metformin to Neoadjuvant Radiochemotherapy in the Treatment of Locally Advanced Rectal Cancer.

NCT07499921Not ApplicableNot Yet RecruitingPrimary

Clinical and BIOgical Analyses of RECtal Tumors

NCT06698289Completed

Preoperative Sarcopenia and Surgical Outcomes in Colorectal Cancer Patients

NCT07369531Not ApplicableRecruitingPrimary

The Impact of Two-Stage Turnbull-Cutait Pull-Through Coloanal Anastomosis on Stoma-free Survival in Low Rectal Anal-preserving Surgery

NCT06628674Not ApplicableRecruitingPrimary

Developing and Testing the Effect of Online Interactive Videos in Improving Low Anterior Resection Syndrome.

NCT06006260CompletedPrimary

Changes of Low Anterior Resection Syndrome and Balance Ability in Patients With Rectal Cancer.

NCT07483060Phase 4Not Yet RecruitingPrimary

Next Generation STAR-TREC (NG-ST) - Organ Preservation in Early Rectal Cancer

NCT03853733RecruitingPrimary

Hypofractionated Palliative Radiotherapy in Patients With Advanced Non-operable Rectal Cancer

Scroll to load more

Research Network

Activity Timeline